Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc. (MRVI) Revenue
Annual & quarterly revenue history · segment & region breakdown
MRVI · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsMaravai LifeSciences Holdings, Inc. trailing twelve-month (TTM) revenue is $0.20B, a decrease of 28.34% year-over-year from $0.19B in FY2025.
Revenue trend
2025 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.19B | -$0.07B | -28.34% |
| 2024-12-31 | $0.26B | -$0.03B | -10.30% |
| 2023-12-31 | $0.29B | -$0.59B | -67.28% |
| 2022-12-31 | $0.88B | +$0.08B | +10.48% |
| 2021-12-31 | $0.80B | +$0.52B | +181.33% |
| 2020-12-31 | $0.28B | +$0.14B | +98.48% |
| 2019-12-31 | $0.14B | +$0.02B | +15.59% |
| 2018-12-31 | $0.12B | — | — |
Compare revenue vs peers
BiotechnologyCompare MRVI revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Maravai LifeSciences Holdings, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Maravai LifeSciences Holdings, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Maravai LifeSciences Holdings, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
MRVI revenue · 4 questionsMRVI's trailing twelve-month (TTM) revenue is $0.20B. That is a decrease of 28.34% year-over-year from $0.19B in FY2025.
▸ Source: FMP · Maravai LifeSciences Holdings, Inc. SEC filings · GAAP · Maravai LifeSciences Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026